Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
– Seasoned biotech executive brings decades of effective financial leadership to Vir –
Mr. O’Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operational execution.
Mr. O’Byrne joins Vir from Caribou Biosciences, Inc., where he served as CFO leading the finance, investor relations, corporate communications, IT, procurement and operations functions as the company advanced its pipeline of clinical-stage cell therapies in oncology and autoimmune disease. Prior to joining Caribou, Mr. O’Byrne served as Senior Vice President of Finance at
Earlier in his career, Mr. O’Byrne held roles of increasing responsibility and geographical reach at
“I am delighted to welcome Jason to the Vir Executive Management Team and excited about the impact he will bring to Vir. Jason’s exceptional leadership coupled with his proven track record in financial strategy across public companies, make him the perfect fit as we embark on the next chapter for our organization,” said
“I am honored to join Vir at this important time as it expands into oncology and continues the innovative work to address unmet patient need in infectious disease,” said Mr. O’Byrne. “I admire Vir’s proven ability to accelerate differentiated antibody therapeutics. I am excited to join the talented team and contribute to rapidly advancing important new therapeutic options for patients.”
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategy and plans, and its expectations related thereto, and potential of, and expectations for, Vir’s pipeline. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; successful development and/or commercialization of alternative product candidates by Vir’s competitors; changes in expected or existing competition; delays in or disruptions to Vir’s business or clinical trials due to geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910506268/en/
Media
Senior Vice President, Corporate Communications
aattridge@vir.bio
Investors
Senior Director, Investor Relations
rlepke@vir.bio
Source:
